DDInter675 DDInter233
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Esmolol {u} (Compound) resembles {v} (Compound) Bisoprolol
Bisoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Esmolol {u} (Compound) resembles {v} (Compound) Bisoprolol
Bisoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Esmolol {u} (Compound) resembles {v} (Compound) Metipranolol
Metipranolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Esmolol {u} (Compound) resembles {v} (Compound) Sotalol
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Esmolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronabinol
Dronabinol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Esmolol {u} (Compound) resembles {v} (Compound) Metipranolol
Metipranolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Esmolol {u} (Compound) resembles {v} (Compound) Sotalol
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Esmolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Esmolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Esmolol (Compound) resembles Metipranolol (Compound) and Metipranolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Esmolol (Compound) resembles Sotalol (Compound) and Sotalol may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Esmolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Esmolol (Compound) resembles Metipranolol (Compound) and Metipranolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Esmolol (Compound) resembles Sotalol (Compound) and Sotalol may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib